 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...132133134135136137138139140141142143144» |
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial withdrawal, Metastases: Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer (clinicaltrials.gov) - Jan 26, 2012
P2, N=0, Withdrawn, Sponsor: Translational Drug Development
Terminated --> Withdrawn
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer (clinicaltrials.gov) - Jan 26, 2012
P2, N=0, Withdrawn, Sponsor: Translational Drug Development
Terminated --> Withdrawn N=60 --> 0
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change: Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract (clinicaltrials.gov) - Jan 26, 2012
P2, N=35, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=60 --> 0 N=60 --> 35
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Combination therapy, Metastases: EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Na (clinicaltrials.gov) - Jan 26, 2012
P2, N=105, Active, not recruiting, Sponsor: EMD Serono
N=60 --> 35 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract (clinicaltrials.gov) - Jan 26, 2012
P2, N=35, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Combination therapy, Metastases: EMR 062202-058: Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer (clinicaltrials.gov) - Jan 24, 2012
P2, N=40, Active, not recruiting, Sponsor: Merck KGaA
Recruiting --> Completed Recruiting --> Active, not recruiting
- | mitomycin / Generic mfg.
Enrollment closed, Surgery, Metastases: Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer (clinicaltrials.gov) - Jan 22, 2012
P3, N=340, Active, not recruiting, Sponsor: Walter Reed Army Medical Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Javlor (vinflunine) / Pierre Fabre, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination: Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC (clinicaltrials.gov) - Jan 19, 2012
P2, N=18, Terminated, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; Drug unavailable
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Jan 16, 2012
P1, N=30, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Terminated; Drug unavailable Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change: Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer (clinicaltrials.gov) - Jan 10, 2012
P=N/A, N=2, Terminated, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting N=20 --> 2
- ||| lumretuzumab (RG7116) / Roche
Enrollment open, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Jan 3, 2012
P1, N=160, Recruiting, Sponsor: Hoffmann-La Roche
N=20 --> 2 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Alternating chemotherapy plus cetuximab to allow resection of metastases from a colorectal cancer that is wild-type KRAS and BRAF - a randomised phase II trial - Nordic 7.6 (EUDRACT) - Jan 2, 2012
P2, N=60, Ongoing, Sponsor: Odense University Hospital
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Preoperative Chemoradiation With Capecitabine and Cetuximab (clinicaltrials.gov) - Dec 28, 2011
P2, N=31, Completed, Sponsor: Austrian Breast & Colorectal Cancer Study Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: H&N07: Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Dec 22, 2011
P3, N=320, Recruiting, Sponsor: Associazione Volontari Pazienti Oncologici
Active, not recruiting --> Completed N=250 --> 320
- HuMax-EGFR (zalutumumab) / Genmab
Enrollment change: GEN206: Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer (clinicaltrials.gov) - Dec 21, 2011
P1/2, N=9, Terminated, Sponsor: Genmab
N=250 --> 320 N=97 --> 9
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: Treatment Selection According to Skin Reaction to Cetuximab (clinicaltrials.gov) - Dec 11, 2011
P2, N=120, Recruiting, Sponsor: Institute of Oncology Ljubljana
N=97 --> 9 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Trial completion: Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer (clinicaltrials.gov) - Nov 30, 2011
P1, N=30, Completed, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma (clinicaltrials.gov) - Nov 29, 2011
P2, N=37, Recruiting, Sponsor: University of Pittsburgh
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: EAGLE: Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (clinicaltrials.gov) - Nov 29, 2011
P2/3, N=243, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Recruiting --> Completed Active, not recruiting --> Recruiting
- ||| lumretuzumab (RG7116) / Roche
New P1 trial, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Nov 28, 2011
P1, N=160, Recruiting, Sponsor: Hoffmann-La Roche
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Surgery: RTOG-0617: High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Nov 24, 2011
P3, N=500, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| telisotuzumab (h224G11) / AbbVie
New P1 trial, Metastases: Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Nov 14, 2011
P1, N=124, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1/2 trial, Combination therapy, Surgery, Metastases: Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Nov 8, 2011
P1/2, N=47, Recruiting, Sponsor: National Cancer Institute (NCI)
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: DREXNECK: Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) - Nov 6, 2011
P2, N=25, Recruiting, Sponsor: Drexel University
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker: Biomarkers in Patients With Head and Neck Cancer (clinicaltrials.gov) - Nov 1, 2011
P=N/A, N=70, Not yet recruiting, Sponsor: Eastern Cooperative Oncology Group
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, New P3 trial, Metastases: Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397 (clinicaltrials.gov) - Nov 1, 2011
P3, N=42, Not yet recruiting, Sponsor: Eastern Cooperative Oncology Group
- ||| sonolisib (PX 866) / Pfizer
Enrollment change: Phase 1 and 2 Study of PX-866 and Cetuximab (clinicaltrials.gov) - Oct 30, 2011
P1/2, N=178, Active, not recruiting, Sponsor: Oncothyreon Inc.
Recruiting --> Active, not recruiting N=144 --> 178
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Treatment Selection According to Skin Reaction to Cetuximab (clinicaltrials.gov) - Oct 22, 2011
P2, N=120, Recruiting, Sponsor: Institute of Oncology Ljubljana
- |||| cixutumumab (IMC A12) / Eli Lilly, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Enrollment open: Preoperative Treatment With Cetuximab and/or IMC-A12 (clinicaltrials.gov) - Oct 17, 2011
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=144 --> 178 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, IO biomarker, Metastases: Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer (clinicaltrials.gov) - Oct 12, 2011
P1, N=21, Terminated, Sponsor: EMD Serono
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; Sponsor will discontinue further development of EMD 1201081
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients (clinicaltrials.gov) - Oct 12, 2011
P2, N=72, Completed, Sponsor: Grupo Hospital de Madrid
- | seribantumab (MM-121) / Elevation Oncology
New P1 trial, Combination therapy, Metastases: A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers (clinicaltrials.gov) - Oct 11, 2011
P1, N=48, Active, not recruiting, Sponsor: Merrimack Pharmaceuticals
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial: MUTEX: Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable Fc?RIIa (CD32) Genotype (clinicaltrials.gov) - Oct 10, 2011
P2, N=72, Active, not recruiting, Sponsor: Merck KGaA
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open: Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) (clinicaltrials.gov) - Oct 10, 2011
P2, N=27, Recruiting, Sponsor: Stanford University
Active, not recruiting --> Terminated; Sponsor will discontinue further development of EMD 1201081 Not yet recruiting --> Recruiting
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) (clinicaltrials.gov) - Oct 2, 2011
P3, N=1861, Completed, Sponsor: Merck KGaA
Not yet recruiting --> Recruiting N=1125 --> 1861
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: OPUS: Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Oct 2, 2011
P2, N=344, Completed, Sponsor: Merck KGaA
N=1125 --> 1861 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1 trial, Combination therapy, Metastases: Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer (clinicaltrials.gov) - Sep 29, 2011
P1, N=3, Completed, Sponsor: National Cancer Institute (NCI)
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 28, 2011
P1/2, N=17, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Recruiting --> Completed
- ||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME) (clinicaltrials.gov) - Sep 28, 2011
P3, N=442, Completed, Sponsor: Merck KGaA
Recruiting --> Completed Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Metastases: Safety and Efficacy Study in Patients With Local Advanced Larynx/Hypolarynx Carcinoma Treated With TPF Induction Chemotherapy Followed by Hyperfractionated Radiotherapy With Cetuximab (clinicaltrials.gov) - Sep 27, 2011
P2, N=70, Terminated, Sponsor: Fundacion Miguel Servet
Active, not recruiting --> Completed Recruiting --> Terminated
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: METHEP-2: Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases (clinicaltrials.gov) - Sep 27, 2011
P2, N=256, Recruiting, Sponsor: UNICANCER
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab (clinicaltrials.gov) - Sep 26, 2011
P2, N=132, Recruiting, Sponsor: UNICANCER
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Surgery, Metastases: EMR 622022237: Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (clinicaltrials.gov) - Sep 21, 2011
P2, N=121, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- ||| cixutumumab (IMC A12) / Eli Lilly, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before (clinicaltrials.gov) - Sep 19, 2011
P2, N=64, Completed, Sponsor: ImClone LLC
Recruiting --> Terminated N=90 --> 64
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer (clinicaltrials.gov) - Sep 19, 2011
P2, N=48, Completed, Sponsor: M.D. Anderson Cancer Center
N=90 --> 64 N=80 --> 48
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer (clinicaltrials.gov) - Sep 19, 2011
P2, N=48, Completed, Sponsor: M.D. Anderson Cancer Center
N=80 --> 48 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial: Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) (clinicaltrials.gov) - Sep 18, 2011
P2, N=27, Recruiting, Sponsor: Stanford University
- ||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 18, 2011
P3, N=939, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial: Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab (clinicaltrials.gov) - Sep 15, 2011
P2, N=303, Completed, Sponsor: Centre Francois Baclesse
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
New P1 trial, Metastases: Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib (clinicaltrials.gov) - Sep 8, 2011
P1, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center